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Aim: To determine which timing of therapy with formoterol (FOR) and/or tiotropium (TIO)
shows the greater and more continuous functional improvement during 24 h in patients with
moderate to severe COPD.
Methods: In this randomised, blind, crossover study 80patientswith stableCOPD (40moderate and
40 severe) received 5 different bronchodilator 30-day treatments in a random order. Treatments
(Tr) were: Tr1: TIO 18 mg once-daily (8 am); Tr2: TIO 18 mg (8 am)þ FOR 12 mg (8 pm); Tr3: FOR
12 mg twice-daily (8 am and 8 pm); Tr4: TIO 18 mg (8 am) þ FOR 12 mg twice-daily (8 am and
8 pm);Tr5: FOR12 mg twice-daily (8 amand8 pm)þ TIO18 mg (8 pm). Spirometrieswereperformed
during24 h (13 steps)onDay1andDay30. End-pointswere: gainofFEV1 (DFEV1) frombaselineof the
Day1 and Day30, AUC (Area Under Curve), Dyspnoea Index, and as-needed use of salbutamol.
Results: Sixty-eightpatients completedall treatments.Thegreater andcontinuousdaily functional
improvement was showed during Tr4 and Tr5 (Day1þ135.8 mL andþ119.1 mL; Day30þ160.2 mL,
and þ160.5 mL, respectively). Daily means of DFEV1 were significantly different between single-
drug treatments and combination therapy. Dyspnoea was greater in single-drug treatments. Less
use of rescue salbutamol was reported in Tr4 (0.80 puffs/die) and Tr5 (0.71 puffs/die).
Conclusions: In patients with moderate to severe COPD, combination therapy with tiotropium
administered in the morning (Tr4) was the most effective; in patients with prevailing night-symp-
toms, treatment with tiotropium in the evening (Tr5) reduced symptoms and use of salbutamol.
Tr5 showed less variability of FEV1 during the 24 h (CVZ 0.256). These results are relevant for
opening new ways in clinical practice.
ª 2008 Elsevier Ltd. All rights reserved.4074517; fax: þ39 06 40800276.
uniroma1.it (A. Petroianni).
8 Elsevier Ltd. All rights reserved.
Table 1 Baseline characteristics of the patients
COPD 40 Moderate, 40 severe
Sex 58 M, 22 F
Age 69.7 7.3
Smoke All ex-smokers
FEV1 pre in L (% predicted) 1.27 0.4 (50% 11.6)
FEV1 post in L (% predicted) 1.37 0.5 (54.3% 11.8)
FVC pre in L (% predicted) 2.34 0.67 (72.3% 10.2)
Mean SD
Patients completing the study
Patients 68
COPD 38 Moderate, 30 severe
Sex 49 M, 19 F
Withdrawn
Exacerbation 2 Moderate, 6 severe
No follow-up 4 Severe
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive disease characterized by irreversible or not fully
reversible airflow obstruction and increasing symptoms of
dyspnoea and limitation in physical activity.
Long-acting bronchodilators, b2-agonists and tiotropium
bromide, are the most effective drugs for controlling
symptoms of COPD.1 The primary aim of treatment is to
relieve symptoms, and to reduce the progression of the
disease and the number of exacerbations.2
Functionally, forced expiratory volume in 1 s (FEV1) is
the widely used parameter for classifying the disease, and
for monitoring the therapeutic effects of these drugs.3
Generally, irreversible airway obstruction shows an
unpredictable and limited response to the bronchodilators
in COPD population. A small number of patients show
a coexistence of COPD and asthma functional features.
Combination therapy with bronchodilators improves
efficacy without additional side effects, compared with
increasing the dose of a single bronchodilator.4
Currently, two types of inhaled long-acting bronchodilators
are commonly utilized in COPD: long-acting b2-agonists
(LABAs) with duration of action of 12 h, and a long-acting
anticholinergic (tiotropium) with duration of action >24 h.1,4
In contrast to LABAs, which have a twice-daily dose
regimen, once-daily tiotropium maintains bronchodilation
over 24 h. Large studies over a period of 1 year showed the
effectiveness of tiotropium in sustaining functional
improvements with no evidence of tolerance.5,6 Combina-
tion therapy of these long-acting agents can provide
important benefits, since these drugs have complementary
actions on the airways.7
Clinical data on combination therapy with tiotropium
and inhaled LABAs have been published in the last years
with an evidence of additive effects in COPD.8 In addition,
long-term studies demonstrated a greater efficacy of tio-
tropium compared to placebo, ipratropium,5,6 as well as to
salmeterol.9
Several studies also showed that tiotropium and LABAs
could lead to hyperinflation reduction, which is accompa-
nied by improvements in exertion dyspnoea and exercise
endurance.10
In their study van Noord et al. reported that a mainte-
nance therapy of combined tiotropium and formoterol,
both once-daily, provides additive effects on FEV1
throughout the 24 h in patients with COPD.11
Add-on therapy of formoterol in the morning to main-
tenance therapy of tiotropium significantly improved FEV1,
forced vital capacity (FVC) and inspiratory capacity (IC) in
COPD. A second formoterol dose in the evening provided
a further improvement in average FEV1, FVC and IC during
the night-time hours.12
COPD patients can differently report symptoms of
dyspnoea and cough during day-time and/or night-time, as
well as the use of rescue salbutamol. Therefore, an accu-
rate timing of bronchodilation therapy is essential to ach-
ieve the best control of airway obstruction and symptoms.
In order to determine the efficacy of bronchodilation
and the best timing of administration, we designed a blind,
randomised, crossover study, in which all the patientsreceived 5 different 30 day-treatments with tiotropium
(TIO) and/or formoterol (FOR).
Patients and methods
Eighty consecutive patients with stable COPD (40 moderate
and 40 severe, ERS/ATS classification) were enrolled from
April 2005 to December 2006. A minimum period of 1 month
without exacerbations was required for inclusion. All the
patients were ex-smokers, and all received an adequate
training in the use of inhalers. Demographic and baseline
characteristics of the patients are reported in Table 1.
Patients with history of asthma, severe cardiovascular
disease, neurological diseases, prostate hyperplasia, glau-
coma, inability to perform lung function test correctly were
excluded. The study was approved by the Hospital Ethics
Committee, and informed written consent was obtained
from each patient.
All the patients received, in random order, 5 different 30
day-treatments with a washout of 96 h between each
treatment, during which patients used salbutamol
metered-dose inhaler (MDI) as-needed.
Tiotropium 18 mg was administrated via HandiHaler dry
powder inhaler (Spiriva), and formoterol 12 mg via
metered-dose inhaler (MDI) (Foradil). Placebo Handihaler
and Placebo MDI were utilized, if drugs were not scheduled.
Inhalation sequence in contemporaneous administration
was FOR as first and subsequently TIO, in all the patients.
Treatments are reported in Fig. 1.
Pre-inhalation spirometry at Day1 and Day30 of each
treatment was performed at 8 am, 10 min before the
morning dose of medication. Spirometry was repeated 50,
30’, 1 h, 2 h, and 10 h after inhalations. In the same way,
spirometries were performed at 8 pm, 10 min before the
second inhalation, and repeated after 50, 30’, 1 h, 2 h, and
10 h. Finally, a 24-h spirometry was performed at 8 am of
the following day (Fig. 1).
A PFT Quark 4 spirometer (Cosmed srl, Pavona, Italy)
was used to measure the functional parameters, and 3 valid
manoeuvres were performed in accordance with
guidelines.13
Rational timing of combination therapy 1703Dyspnoea was assessed with the Baseline and Transi-
tional Dyspnoea Index (BDI/TDI).14 In comparison to Base-
line Dyspnoea Index (Day1), Transitional Dyspnoea Index
measured the changes in functional impairment (from þ3
to 3), magnitude of task (from þ3 to 3), and magnitude
effort (from þ3 to 3).
Patients were trained in the appropriate daily recording
on a diary of as-needed use of salbutamol MDI during the
treatments. The use of salbutamol was recorded separately
for day-time (8 ame8 pm) and night-time (8 pme8 am).
Details of clinical status, BDI/TDI, adverse events, and
withdrawals were recorded at the beginning and at the end
of each treatment.
Data analysis
The primary efficacy end-point was the DFEV1 (in mL),
calculated as the difference between FEV1 value of each
step during 24 h and the baseline FEV1 (FEV1 at time 0 of
Day1 of each treatment). Secondary end-points were
Dyspnoea Index (BDI/TDI) and the as-needed use of
salbutamol.
All values are expressed as means SD (Standard Devi-
ation). Daily mean DFEV1 is the mean bronchodilation over
24 h for each treatment. Area Under Curve (AUC) was
calculated for each treatment on Day1 and Day30 to assess
the 24 h bronchodilation. At steady state, Coefficient of
Variation (CVZ Standard Deviation (SD)/mean) of the daily
mean DFEV1 was considered to assess the variability of
bronchodilation over 24 h.
Statistical analysis was performed with Prism 4 Graph-
Pad Software. A two-tailed, paired T test, with confidence
intervals of 95%, was carried out to analyse the difference
between Day1 and Day30 and among each treatment. One-
way ANOVA with repeated measure test and Bonferroni
post-test was carried out to compare all the treatments at
Day1 and Day30. P values< 0.05 were considered
significant.
BDI/TDI index of dyspnoea was calculated as the addi-
tion of improvement in functional impairment, magnitude
of task, and magnitude of effort (ANOVA).8 AM 8 PM
Spirometric Assessment (DAY1 and DAY30)
Time 0  5’ 30’ 1h  2h
Treatment 1 
Treatment 2 
Treatment 3 
Treatment 4 
Treatment 5 
TIO Hand.+Placebo MDI 
FOR MDI+Placebo Hand. 
TIO Hand.+Placebo MDI  
TIO Hand.+FOR MDI  
FOR MDI+Placebo Hand.
8 AM 
130’5’12h10h
Figure 1 Thirty-day treatments and functional assessment at Da
order all the treatments.Results
Sixty-eight patients (49 M, 19 F; 38 with moderate and 30 with
severe COPD) completed all the treatments. Twelve patients
prematurely discontinued the study: 8 patients because of
exacerbations (2 with moderate and 6 with severe COPD), and
4 patients with severe COPD because of unavailability at
follow-up (Table 1). There were no notable side effects.
Twenty-four hours improvements of FEV1 (DFEV1) in mL
and AUC, on Day1 and Day30, for all the treatments are
reported in Table 2 and 3.
On Day1, Tr4 showed the best daily mean functional
improvement of FEV1 (DFEV1 þ135.8 65.9 mL, AUC
197,708). Other combination treatments, Tr2 (DFEV1
þ109.8 mL, AUC 171,343) and Tr5 (DFEV1 þ119.1 mL, AUC
175,675), showed a greater effect than single-drug treat-
ments, Tr1 (DFEV1 þ60.2 mL, AUC 98,060) and Tr3 (DFEV1
þ86.2 mL, AUC 114,485). During 24 h of Day1, less bron-
chodilation variability was observed in Tr4 and Tr5
(CVZ 0.485 and 0.524, respectively) (Table 3).
On Day30, combination treatments confirmed the
significant greater daily bronchodilation, especially in full
dosage treatments of Tr4 (DFEV1 þ160.2 mL, AUC 222,518)
and Tr5 (DFEV1 þ160.5 mL, AUC 226,235).
At steady state, Tr1 (TIO once-daily) showed a significant
improvement of daily mean DFEV1 (þ75.6 mL) compared to
Day1 value (þ60.2 mL) (pZ 0.0032). On the contrary in Tr3
(FOR twice-daily), a not significant decrement of daily
mean DFEV1 was observed at Day30 (þ79 mL) compared
with the Day1 value (þ86.2 mL) (pZ 0.22).
Comparing treatments with single-drug (Tr1 and Tr3) not
significant differences were observed at Day1 (pZ 0.077)
and Day30 (pZ 0.788).
Daily mean DFEV1 and AUC were significantly different
between treatments with single drug (Tr1 and Tr3) and
treatments with combination of tiotropium and formoterol
(Tr2, Tr4, and Tr5) (Table 4).
Significant differences in mean DFEV1 and AUC were
observed between the Day1 and Day30 in Tr1, Tr2, Tr4, and
Tr5. Statistical analysis of DFEV1 comparing each treatment
was reported in Table 4. 
Placebo MDI+Placebo Hand.
FOR  MDI+Placebo Hand.
FOR  MDI+Placebo Hand.
FOR  MDI+Placebo Hand.
TIO  Hand+FOR MDI
8 PM
8 AM
24h22h2hh
y1 and Day30 of each treatment. Patients received in random
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1704 C. Terzano et al.In addition, at Day30 (steady state), Tr5 showed the
greater functional 24 h-improvement (daily mean DFEV1) in
comparison to Day1: (daily mean DFEV1 of Day30 daily
mean DFEV1 of Day1Z) Tr1: þ15.4 mL (AUC þ27,655), Tr2:
þ18.4 mL (AUC þ13,195), Tr3: 7.2 mL (AUC 7287), Tr4:
þ24.4 mL (AUC þ24,810), and Tr5: þ41.4 mL (AUC
þ50,560).
During the Day30, an interesting pharmacodynamic
behaviour of formoterol was observed in Tr4 and Tr5: after
the contemporaneous administration of FOR and TIO (Tr4 in
the morning, and Tr5 in the evening) the post 50 spirometry
showed less functional improvement (Tr4 þ172 mL, Tr5
þ138 mL) than administration of formoterol alone (Tr4
þ189 mLandTr5þ205 mL). This behaviour resulted inverted
in post 300, 1 h, and 2 h spirometric measurements (Table 2).
BDI/TDI showed a greater improvement of symptoms in
treatments with combination therapy than single drug
(pZ 0.0004) (Table 5).
The evaluation of as-needed use of salbutamol showed
a greater number of administrations during Tr1 (a mean of
2.14 puffs/die) than other treatments. Less use was
reported during Tr4 and Tr5 (a mean of 0.80 puffs/die and
0.71 puffs/die, respectively). Use of salbutamol was
generally less during the night-time in all the treatments.
Mean of puffs/die was reported in Table 5.Discussion
This study investigated the possible variable effects of
a different timing in administration of bronchodilator
drugs, alone and in combination, in stable moderate and
severe COPD.
As reported in recent relevant studies, combination of
tiotropium and formoterol shows a superior bronchodila-
tion efficacy compared to either of them administered
separately.11,12,15e17
The aim of our study was to find out the best timing of
administration for these drugs.
Generally in other studies authors’ questions about
therapy were: what and how to administer. In this study our
main question was: when during the 24 h.
A rational timing, keeping a constant daily bronchodi-
lation, may be a further chance to improve the effects of
therapy in COPD patients, improving functional parame-
ters, quality of life, and potentially decreasing the
frequency of exacerbations.
In this crossover study, the subjects received all the treat-
ments in random order, avoiding interindividual variability. A
washout period of 96 h between each treatment was applied.
The random order of administration reduced the possible
interference of the residual effect of prior tiotropium.
Conducted on stable moderate and severe COPD
patients, our study was designed in order to collect data on
reversibility, symptoms, and rescue salbutamol. Therefore
periods of treatments were limited at 30 days. In this way,
it was not possible to determine the evaluation on exac-
erbations or long-term loss of functional capacity.
Authors did not consider studying a 6th regimen with TIO
8 am and FOR 8 am, which was one of the regimens
reported in van Noord’s paper,11 because our study aimed
to achieve a constant bronchodilation during the 24 h.
Table 3 AUC (Area Under Curve) and CV (coefficient of
variation) at Day1 and Day30 of each treatment (Tr)
AUC CV
Day1
Tr 1 e TIO 8 am 98,060 0.846
Tr 2 e TIO 8 am, and FOR 8 pm 171,343 0.561
Tr 3 e FOR 8 am, and FOR 8 pm 114,485 0.699
Tr 4 e TIOþ FOR 8 am, and FOR 8 pm 197,708 0.485
Tr 5 e FOR 8 am, and TIOþ FOR 8 pm 175,675 0.524
Day30
Tr 1 e TIO 8 am 125,715 0.548
Tr 2 e TIO 8 am, and FOR 8 pm 184,538 0.402
Tr 3 e FOR 8 am, and FOR 8 pm 107,198 0.541
Tr 4 e TIOþ FOR 8 am, and FOR 8 pm 222,518 0.331
Tr 5 e FOR 8 am, and TIOþ FOR 8 pm 226,235 0.256
Rational timing of combination therapy 1705This study was performed applying 2 single-drug treat-
ments (Tr1 and Tr3) with standard dosage, and 2 combi-
nation treatments of formoterol and tiotropium (Tr4 and
Tr5) with different timing of administration (Tiotropium in
the morning or in the evening). Tr2 (Tiotropium once-daily
and formoterol once-daily) was considered to compare the
results of recent studies on this type of administration.8,12
Spirometric measurements were similarly distributed
during the day-time (6) and the night-time (6), in order to
have an equal weight on data analysis. However, in this
study lung volumes were not measured, mainly because this
study is rather complex to allow these measurements to be
performed as well. It would have been important to show
the correlation between improvement in the dyspnea index
and IC.
At Day1 and Day30, combination treatments confirmed
the significant greater daily bronchodilation, especially in
full dosage treatments (Tr4 and Tr5), than single-drug
treatments.
Interestingly, at steady state, Tr1 showed an improve-
ment of daily mean DFEV1 compared with Day1 value
(pZ 0.0032); whereas in Tr3 a not significant decrement of
daily mean DFEV1 was observed at Day30 compared with
Day1 (pZ 0.22). This decrement may be hardly linked to
a rapid beta-receptor tolerance. In fact, several long-termTable 4 Statistical analysis of daily DFEV1 and AUC (ANOVA and
Day1 vs Day30
Tr 1 e TIO 8 am 0.003*
Tr 2 e TIO 8 am, and FOR 8 pm 0.006*
Tr 3 e FOR 8 am, and FOR 8 pm 0.221
Tr 4 e TIOþ FOR 8 am, and FOR 8 pm 0.009*
Tr 5 e FOR 8 am, and TIOþ FOR 8 pm 0.003*
ANOVA
All treats at Day1 0.0001*
All treats at Day30 0.0001*
*p< 0.05studies have shown no tolerance to the bronchodilation
effect of formoterol in COPD.18,19
In our study at Day1 and Day30, formoterol twice-daily
provided a not significant difference in bronchodilation
than tiotropium once-daily.
In Tr4 and Tr5, the pharmacodynamic behaviour of the
contemporaneous administration of FOR and TIO, showing
a less functional improvement in the post 50 spirometry
than administration of formoterol alone, was an intriguing
result. This behaviour resulted inverted in the post 300, 1 h,
and 2 h spirometric measurements.
A hypothetical mechanism of that feature might be the
effect of TIO powder. It might delay the bronchodilation
effect of FOR MDI for a few minutes, when contempora-
neously administered. This is supposedly associated to
a mild provoking effect of the powder on airway smooth
muscle or a delayed effect when the two different bron-
chodilating receptors are activated at the same time. It
would be interesting to confirm this hypothesis in next
studies comparing the early effect of FOR MDI and FOR DPI
during 24 h in moderate and severe COPD and asthma.
As supposed in some studies,11,20 nocturnal administra-
tion of combination therapy may be linked to a modulation
of anticholinergic effect on bronchial receptors (vagal
tone), and to a synergism with adrenergic system. An
endogenous circadian rhythm may play an important and
intricate role in the circadian modulation of the inflam-
matory processes, and susceptibility of airway smooth
muscle and vasculature. In fact, an increase in vagal tone
may induce nocturnal bronchoconstriction which is further
enhanced by falling catecholamine levels. This is consistent
with the findings by Postma et al.,20 who demonstrated that
activity of adrenergic system is most prominent during the
day; whereas an increased activity of parasympathetic
system was found during the night. Compared with normal
controls, this vagal activity appeared significantly increased
in COPD patients.20
Moreover, in the nocturnal administration, anticholin-
ergic effect on mucus glands can be exploited for inhibition
of mucus secretion, and consequent reduction of nocturnal
bronchial build-up.7
At steady state, further important result was the minor
bronchodilation variability of Tr5 during the 24 h (CV 0.256).
As previously shown by van Noord et al.,15 in our study an
optimal bronchodilation response by tiotropium wasT test)
Day1 Day30
Tr 1 vs Tr 2 0.007* 0.001*
Tr 1 vs Tr 3 0.077 0.788
Tr 1 vs Tr 4 0.0005* 0.0001*
Tr 1 vs Tr 5 0.015* 0.0001*
Tr 2 vs Tr 3 0.017* 0.0001*
Tr 2 vs Tr 4 0.0007* 0.0001*
Tr 2 vs Tr 5 0.311 0.004*
Tr 3 vs Tr 4 0.0001* 0.0001*
Tr 3 vs Tr 5 0.033* 0.0001*
Tr 4 vs Tr 5 0.160 0.946
T test *p< 0.05
Table 5 BDI/TDI index of dyspnoea (mean SD) and rescue salbutamol
Dyspnoea Mean of puffs of salbutamol as needed/die
Baseline DI (68 pts) Grade 2.17 0.72 Transitional DI
(68 pts)
8 ame8 pm
day-time
8 pme8 am
night-time
TOT. puffs/die
Tr 1 TIO 8 am þ1.0 1.59 1.51 0.63 2.14
Tr 2 TIO 8 am, and FOR 8 pm þ1.5 1.44 1.38 0.23 1.61
Tr 3 FOR 8 am, and FOR 8 pm þ1.38 1.61 1.15 0.38 1.53
Tr 4 TIOþ FOR 8 am, and FOR 8 pm þ2.61 2.0* 0.59 0.21 0.80*
Tr 5 FOR 8 am, and TIOþ FOR 8 pm þ2.32 1.77* 0.65 0.05 0.71*
T test *p< 0.05 T test *p< 0.05
1706 C. Terzano et al.achieved in pharmacodynamic steady state. It means that
conclusions on pulmonary effects of the single drugs in
relation to their combination can only be assessed following
maintenance therapy.
On the other hand, in our study, Tr4 showed some
advantages compared with other treatments: a rapid
achievement of high bronchodilation values already in the
first day of treatment (AUC 197,708), and the attainment of
the highest bronchodilation peaks during the 24 h.
In this study, Dyspnoea Index showed a significant improve-
ment of symptoms in combination treatments, confirming their
superiority on other treatments in reducing symptoms.
In addition, daily as-needed use of salbutamol was
significantly less during treatments with combination regi-
mens. Previous studies in COPD have also shown less sal-
butamol consumption during the night-time.21 In our study
use of reliever medications was significantly less during the
night-time and patients required lower daily use of salbu-
tamol during Tr5 (Table 5).
In the study conducted by van Noord et al.,11 comparing
the effects of TIO and FOR, the most pronounced bron-
chodilation effect was achieved with the combination
treatment. Confirming these data, our study completes the
knowledge on bronchodilation effects of these drugs. In
fact, we can assert that combinations Tr4 and Tr5, with TIO
administered in the morning or in the evening, allow to
achieve a greater and constant level of bronchodilation in
the 24 h than treatment with TIO and FOR once-daily (Tr2 in
our study).
Certainly, the different administration of TIO (in the
morning or in the evening), can be preferred in relation to
the patient’s characteristics (daily activity, nocturnal
dyspnoea, etc.). Van Noord15 observed once-daily TIO
provides more bronchodilation during day-time compared
with twice-daily FOR, and no different results between the
two long-acting bronchodilator treatment regimens during
the night-time. In our study FOR twice-daily and TIO once-
daily showed a similar 24 h bronchodilation at steady state,
although TIO once-daily provides more bronchodilation
during the first 12 h, whereas FOR twice-daily shows
a greater bronchodilation in the second 12 h.
Conclusion
As recommended by the Global Initiative for Chronic
Obstructive Lung Disease guidelines,2 a combination of two
long-acting bronchodilators with different pharmacologicalmechanisms of action should be considered in all patients
with moderate to severe COPD.
In terms of improvement in lung function, combination of
formoterol and tiotropium is more effective in patients with
moderate to severe COPD than single drugs administered alone.
In our crossover study, the most effective timing to achieve
a constant and greater bronchodilation was resulted in Tr4 and
Tr5. These results are important to assure the best level of
bronchodilation in COPD patients, and to use such combination
for such patients in clinical practice.
A rational timing for administration of the combination
therapy, in the morning or in the evening, can be selected
in relation to COPD patient’s characteristics.
Our study can open the way to trials with combination
therapy in different timing of administration, monitoring
nocturnal hypoxic episodes, sleep disorders, as-needed use
of salbutamol, and the correlation with the activity of
adrenergic system during the day and the activity of para-
sympathetic system during the night. Although present
study supplies new data, it can be considered a preliminary
one supporting the design of new projects on long-term
impact of a given timing of administration on exacerba-
tions, quality of life, and lung function loss. This study may
open the way to a therapy modelled on the COPD patients’
characteristics.Conflict of interest statement
The authors have no conflict of interest.
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